Hormone replacement therapy, cancer, controversies, and women's health: Historical, epidemiological, biological, clinical, and advocacy perspectives

Nancy Krieger, Ilana Löwy, Robert Aronowitz, Judyann Bigby, Kay Dickersin, Elizabeth Garner, Jean Paul Gaudillière, Carolina Hinestrosa, Ruth Hubbard, Paula A. Johnson, Stacey A. Missmer, Judy Norsigian, Cynthia Pearson, Charles E. Rosenberg, Lynn Rosenberg, Barbara G. Rosenkrantz, Barbara Seaman, Carlos Sonnenschein, Ana M. Soto, Joe ThorntonGeorge Weisz

Research output: Contribution to journalArticle

Abstract

Routine acceptance of use of hormone replacement therapy (HRT) was shattered in 2002 when results of the largest HRT randomised clinical trial, the women's health initiative, indicated that long term use of oestrogen plus progestin HRT not only was associated with increased risk of cancer but, contrary to expectations, did not decrease, and may have increased, risk of cardiovascular disease. In June 2004 a group of historians, epidemiologists, biologists, clinicians, and women's health advocates met to discuss the scientific and social context of and response to these findings. It was found that understanding the evolving and contending knowledge on hormones and health requires: (1) considering its societal context, including the impact of the pharmaceutical industry, the biomedical emphasis on individualised risk and preventive medicine, and the gendering of hormones; and (2) asking why, for four decades, since the mid-1960s, were millions of women prescribed powerful pharmacological agents already demonstrated, three decades earlier, to be carcinogenic? Answering this question requires engaging with core issues of accountability, complexity, fear of mortality, and the conduct of socially responsible science.

Original languageEnglish (US)
Pages (from-to)740-748
Number of pages9
JournalJournal of Epidemiology and Community Health
Volume59
Issue number9
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Women's Health
Hormones
Neoplasms
Precision Medicine
Preventive Medicine
Social Responsibility
Drug Industry
Progestins
Fear
Estrogens
Cardiovascular Diseases
Randomized Controlled Trials
Pharmacology
Mortality
Health

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Hormone replacement therapy, cancer, controversies, and women's health : Historical, epidemiological, biological, clinical, and advocacy perspectives. / Krieger, Nancy; Löwy, Ilana; Aronowitz, Robert; Bigby, Judyann; Dickersin, Kay; Garner, Elizabeth; Gaudillière, Jean Paul; Hinestrosa, Carolina; Hubbard, Ruth; Johnson, Paula A.; Missmer, Stacey A.; Norsigian, Judy; Pearson, Cynthia; Rosenberg, Charles E.; Rosenberg, Lynn; Rosenkrantz, Barbara G.; Seaman, Barbara; Sonnenschein, Carlos; Soto, Ana M.; Thornton, Joe; Weisz, George.

In: Journal of Epidemiology and Community Health, Vol. 59, No. 9, 09.2005, p. 740-748.

Research output: Contribution to journalArticle

Krieger, N, Löwy, I, Aronowitz, R, Bigby, J, Dickersin, K, Garner, E, Gaudillière, JP, Hinestrosa, C, Hubbard, R, Johnson, PA, Missmer, SA, Norsigian, J, Pearson, C, Rosenberg, CE, Rosenberg, L, Rosenkrantz, BG, Seaman, B, Sonnenschein, C, Soto, AM, Thornton, J & Weisz, G 2005, 'Hormone replacement therapy, cancer, controversies, and women's health: Historical, epidemiological, biological, clinical, and advocacy perspectives', Journal of Epidemiology and Community Health, vol. 59, no. 9, pp. 740-748. https://doi.org/10.1136/jech.2005.033316
Krieger, Nancy ; Löwy, Ilana ; Aronowitz, Robert ; Bigby, Judyann ; Dickersin, Kay ; Garner, Elizabeth ; Gaudillière, Jean Paul ; Hinestrosa, Carolina ; Hubbard, Ruth ; Johnson, Paula A. ; Missmer, Stacey A. ; Norsigian, Judy ; Pearson, Cynthia ; Rosenberg, Charles E. ; Rosenberg, Lynn ; Rosenkrantz, Barbara G. ; Seaman, Barbara ; Sonnenschein, Carlos ; Soto, Ana M. ; Thornton, Joe ; Weisz, George. / Hormone replacement therapy, cancer, controversies, and women's health : Historical, epidemiological, biological, clinical, and advocacy perspectives. In: Journal of Epidemiology and Community Health. 2005 ; Vol. 59, No. 9. pp. 740-748.
@article{c5c98529cbcb4afabbe17f3578b8c35d,
title = "Hormone replacement therapy, cancer, controversies, and women's health: Historical, epidemiological, biological, clinical, and advocacy perspectives",
abstract = "Routine acceptance of use of hormone replacement therapy (HRT) was shattered in 2002 when results of the largest HRT randomised clinical trial, the women's health initiative, indicated that long term use of oestrogen plus progestin HRT not only was associated with increased risk of cancer but, contrary to expectations, did not decrease, and may have increased, risk of cardiovascular disease. In June 2004 a group of historians, epidemiologists, biologists, clinicians, and women's health advocates met to discuss the scientific and social context of and response to these findings. It was found that understanding the evolving and contending knowledge on hormones and health requires: (1) considering its societal context, including the impact of the pharmaceutical industry, the biomedical emphasis on individualised risk and preventive medicine, and the gendering of hormones; and (2) asking why, for four decades, since the mid-1960s, were millions of women prescribed powerful pharmacological agents already demonstrated, three decades earlier, to be carcinogenic? Answering this question requires engaging with core issues of accountability, complexity, fear of mortality, and the conduct of socially responsible science.",
author = "Nancy Krieger and Ilana L{\"o}wy and Robert Aronowitz and Judyann Bigby and Kay Dickersin and Elizabeth Garner and Gaudilli{\`e}re, {Jean Paul} and Carolina Hinestrosa and Ruth Hubbard and Johnson, {Paula A.} and Missmer, {Stacey A.} and Judy Norsigian and Cynthia Pearson and Rosenberg, {Charles E.} and Lynn Rosenberg and Rosenkrantz, {Barbara G.} and Barbara Seaman and Carlos Sonnenschein and Soto, {Ana M.} and Joe Thornton and George Weisz",
year = "2005",
month = "9",
doi = "10.1136/jech.2005.033316",
language = "English (US)",
volume = "59",
pages = "740--748",
journal = "Journal of Epidemiology and Community Health",
issn = "0143-005X",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Hormone replacement therapy, cancer, controversies, and women's health

T2 - Historical, epidemiological, biological, clinical, and advocacy perspectives

AU - Krieger, Nancy

AU - Löwy, Ilana

AU - Aronowitz, Robert

AU - Bigby, Judyann

AU - Dickersin, Kay

AU - Garner, Elizabeth

AU - Gaudillière, Jean Paul

AU - Hinestrosa, Carolina

AU - Hubbard, Ruth

AU - Johnson, Paula A.

AU - Missmer, Stacey A.

AU - Norsigian, Judy

AU - Pearson, Cynthia

AU - Rosenberg, Charles E.

AU - Rosenberg, Lynn

AU - Rosenkrantz, Barbara G.

AU - Seaman, Barbara

AU - Sonnenschein, Carlos

AU - Soto, Ana M.

AU - Thornton, Joe

AU - Weisz, George

PY - 2005/9

Y1 - 2005/9

N2 - Routine acceptance of use of hormone replacement therapy (HRT) was shattered in 2002 when results of the largest HRT randomised clinical trial, the women's health initiative, indicated that long term use of oestrogen plus progestin HRT not only was associated with increased risk of cancer but, contrary to expectations, did not decrease, and may have increased, risk of cardiovascular disease. In June 2004 a group of historians, epidemiologists, biologists, clinicians, and women's health advocates met to discuss the scientific and social context of and response to these findings. It was found that understanding the evolving and contending knowledge on hormones and health requires: (1) considering its societal context, including the impact of the pharmaceutical industry, the biomedical emphasis on individualised risk and preventive medicine, and the gendering of hormones; and (2) asking why, for four decades, since the mid-1960s, were millions of women prescribed powerful pharmacological agents already demonstrated, three decades earlier, to be carcinogenic? Answering this question requires engaging with core issues of accountability, complexity, fear of mortality, and the conduct of socially responsible science.

AB - Routine acceptance of use of hormone replacement therapy (HRT) was shattered in 2002 when results of the largest HRT randomised clinical trial, the women's health initiative, indicated that long term use of oestrogen plus progestin HRT not only was associated with increased risk of cancer but, contrary to expectations, did not decrease, and may have increased, risk of cardiovascular disease. In June 2004 a group of historians, epidemiologists, biologists, clinicians, and women's health advocates met to discuss the scientific and social context of and response to these findings. It was found that understanding the evolving and contending knowledge on hormones and health requires: (1) considering its societal context, including the impact of the pharmaceutical industry, the biomedical emphasis on individualised risk and preventive medicine, and the gendering of hormones; and (2) asking why, for four decades, since the mid-1960s, were millions of women prescribed powerful pharmacological agents already demonstrated, three decades earlier, to be carcinogenic? Answering this question requires engaging with core issues of accountability, complexity, fear of mortality, and the conduct of socially responsible science.

UR - http://www.scopus.com/inward/record.url?scp=23844512186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844512186&partnerID=8YFLogxK

U2 - 10.1136/jech.2005.033316

DO - 10.1136/jech.2005.033316

M3 - Article

C2 - 16100311

AN - SCOPUS:23844512186

VL - 59

SP - 740

EP - 748

JO - Journal of Epidemiology and Community Health

JF - Journal of Epidemiology and Community Health

SN - 0143-005X

IS - 9

ER -